We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+34.21%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$8.57B
AUM Growth
+$1.33B
Cap. Flow
+$552M
Cap. Flow %
6.44%
Top 10 Hldgs %
58.85%
Holding
53
New
11
Increased
15
Reduced
3
Closed
7

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$238M
2
VERA icon
Vera Therapeutics
VERA
+$188M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$170M
4
VKTX icon
Viking Therapeutics
VKTX
+$160M
5
MGNX icon
MacroGenics
MGNX
+$93M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$287M
2
CBAY
Cymabay Therapeutics
CBAY
+$262M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$135M
4
GPCR icon
Structure Therapeutics
GPCR
+$95.1M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
26
Spyre Therapeutics
SYRE
$9.2B
$69.8M 0.81%
1,839,138
– –
SLNO
27
DELISTED
Soleno Therapeutics
SLNO
$69.5M 0.81%
1,625,000
+840,000
+107% +$38M
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.4B
$66.3M 0.77%
13,050,000
– –
OCUL icon
29
Ocular Therapeutix
OCUL
$2.01B
$65.1M 0.76%
+7,148,936
New +$50.7M
TSHA icon
30
Taysha Gene Therapies
TSHA
$1.86B
$53.5M 0.62%
18,650,000
+14,294,445
+328% +$29.8M
TRML
31
DELISTED
Tourmaline Bio
TRML
$50.9M 0.59%
2,222,222
+1,353,815
+156% +$47.7M
ROIV icon
32
Roivant Sciences
ROIV
$26.2B
$49M 0.57%
4,651,162
– –
ALNY icon
33
Alnylam Pharmaceuticals
ALNY
$29.2B
$44.8M 0.52%
300,000
-811,111
-73% -$135M
MNKD icon
34
MannKind Corp
MNKD
$1.32B
$40.8M 0.48%
9,000,000
– –
MRUS
35
DELISTED
Merus
MRUS
$40M 0.47%
888,888
– –
PCVX icon
36
Vaxcyte
PCVX
$8.62B
$39.3M 0.46%
+575,000
New +$39.8M
RARE icon
37
Ultragenyx Pharmaceutical
RARE
$2.55B
$38.8M 0.45%
830,000
+480,000
+137% +$22.6M
MRNS
38
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$37.4M 0.44%
4,140,607
+990,607
+31% +$9.63M
RCKT icon
39
Rocket Pharmaceuticals
RCKT
$391M
$34M 0.4%
1,260,900
– –
GLUE icon
40
Monte Rosa Therapeutics
GLUE
$1.35B
$32M 0.37%
4,535,000
– –
CGON icon
41
CG Oncology
CGON
$6.59B
$30.7M 0.36%
+700,000
New +$28.6M
CRSP icon
42
CRISPR Therapeutics
CRSP
$5.19B
$28.6M 0.33%
+419,580
New +$30M
VRCA icon
43
Verrica Pharmaceuticals
VRCA
$93.6M
$23.7M 0.28%
400,000
– –
KYTX icon
44
Kyverna Therapeutics
KYTX
$482M
$11.8M 0.14%
+475,000
New +$13.3M
WHWK
45
Whitehawk Therapeutics
WHWK
$234M
$6.67M 0.08%
2,849,402
– –
ADVM
46
DELISTED
Adverum Biotechnologies
ADVM
$5.89M 0.07%
+416,666
New +$6.34M
FENC icon
47
Fennec Pharmaceuticals
FENC
$404M
– –
-1,200,000
Closed -$13.5M
GPCR icon
48
Structure Therapeutics
GPCR
$3.73B
– –
-2,333,333
Closed -$95.1M
NUVL
49
DELISTED
Nuvalent
NUVL
– –
-178,921
Closed -$13.2M
CBAY
50
DELISTED
Cymabay Therapeutics
CBAY
– –
-11,111,111
Closed -$262M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Avoro Capital Advisors held 53 positions worth $8.57B, up 18% from $7.24B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Avoro Capital Advisors deployed $552M of net new capital in Q1 2024, opening 11 new positions and adding to 15 existing holdings. Its largest new stake was Vera Therapeutics: 5,265,000 shares worth $227M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $135M trimmed.

  • Avoro Capital Advisors's largest Q1 2024 buy was Vera Therapeutics: 5,265,000 shares worth $227M.
  • Avoro Capital Advisors added most to Arrowhead Research in Q1 2024, an estimated $238M increase.
  • Avoro Capital Advisors's biggest Q1 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $135M.
  • Avoro Capital Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $287M.
  • Avoro Capital Advisors's ten largest holdings make up 59% of its $8.57B portfolio in Q1 2024.
  • Avoro Capital Advisors opened 11 new positions and closed 7 in Q1 2024.
  • Avoro Capital Advisors's portfolio value rose 18% quarter-over-quarter to $8.57B.

Based on Avoro Capital Advisors's 13F filing for Q1 2024, filed 15 May 2024.